1. no documented infection with sars-cov-2. 2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement \>4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma \[including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection\], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

1. no documented infection with sars-cov-2. 2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement \>4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma \[including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection\], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

no documented infection with sars-cov-2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement >4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

no documented infection with sars-cov-2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement >4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

1. no documented infection with sars-cov-2. 2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement >4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

1. no documented infection with sars-cov-2. 2. patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (ordinal scale for clinical improvement >4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed or without eua) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

1. no documented infection with sars-cov-2. 2. patients who require oxygen (ordinal scale for clinical improvement >3) at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

1. no documented infection with sars-cov-2. 2. patients who require oxygen (ordinal scale for clinical improvement >3) at the time of screening. 3. known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 4. exposure to any investigational therapy (defined as any agent not currently marketed) at the time of or within 30 days prior to the screening visit. 5. any condition which, in the opinion of the principal investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints